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control interventions in blinded
pharmacological randomised clinical trials:
a methodological systematic review
Segun Bello1,2*, Maoling Wei3, Jørgen Hilden4 and Asbjørn Hróbjartsson1,5
Abstract
Background: Blinding is a pivotal method to avoid bias in randomised clinical trials. In blinded drug trials, experimental
and control interventions are often designed to be matched, i.e. to appear indistinguishable. It is unknown how often
matching procedures are inadequate, so we decided to systematically identify and analyse studies of matching quality
in drug trials. Our primary objective was to assess the proportion of studies that concluded that the matching was
inadequate; our secondary objective was to describe mechanisms for inadequate matching.
Methods: Systematic review. We searched PubMed, Google Scholar and Web of Science Citation Index for studies that
assessed whether supposedly indistinguishable interventions (experimental and control) in randomized clinical drug
trials could be distinguished based on physical properties (e.g. appearance or smell). Two persons decided on
study eligibility and extracted data independently. Our primary analysis was based on the conclusions of each
study. In supportive analyses, we defined a low and a high threshold for inadequate matching. We summarised
results qualitatively.
Results: We included studies of 36 trials, of which 28 (78 %) were published before 1977. The studies differed
considerably with regard to design, methodology and analysis. Sixteen of the 36 studies (44 %) concluded
inadequate matching. When we adapted high or low thresholds for inadequate matching, the number of trials with
inadequate matching was reduced to 12 (33 %) or increased to 26 (72 %). Inadequate matching was concluded in 7 of
22 trials (32 %) based on a defined cohort of trials. Inadequate matching was concluded in 9 of 14 trials (64 %) which
were not based on a trial cohort, and therefore at a higher risk of publication bias. The proportion of inadequate
matching did not seem to depend on publication year. Typical mechanisms of inadequate matching were
differences in taste or colour.
Conclusion: We identified matching quality studies of 36 randomized clinical drug trials. Sixteen of the 36 studies
(44 %) concluded inadequate matching. Few studies of matching quality in contemporary trials have been published,
but show similar results as found for older trials. Inadequate matching in drug trials may be more prevalent than
commonly believed.
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Background
Blinding is a pivotal methodological principle in rando-
mised clinical trials [1, 2]. Blinding reduces the risk of bias
in a trial by masking which intervention is experimental
and which is control. The degree of bias in trials with non-
blinded patients, treatment providers or outcome asses-
sors can be pronounced [3–7]. For example, lack of
blinding of outcome assessors exaggerates odds ratios by
approximately 36 %, on average in trials with subjective
outcomes (i.e. involving assessor judgment) [4].
Pharmacological trials constitute approximately 75 %
of conducted trials [8], and have a profound influence
on clinical medicine. A blinded drug trial typically com-
pares an experimental drug intervention with a matched
control intervention, i.e. one that appears identical to
the experimental intervention, but which does not contain
the essential component of the drug under investigation.
Matching is implemented in more than 90 % of pharmaco-
logical trials which report blinding methods [9]. Matching
is therefore the fundamental blinding procedure in drug
trials, providing the basis for simultaneous blinding of
patients, treatment providers and outcome assessors.
Pharmacological interventions have different prepar-
ation formats such as tablets, capsules, aerosols, liquid,
or ointment, and may contain substances that affect
taste, texture, appearance, viscosity, or odour. Matching
procedures may differ; for example, tablets may be embed-
ded in identically appearing capsules, or specific flavours
may be added to oral medicaments to mask a distinct
taste, or similar opaque syringes may be used for injection
to convey otherwise distinguishable solutions [9]. Rarely,
active placebos are used to mimic the side effects of the
experimental intervention [10]. More common is the
double-dummy approach (i.e. active A + placebo B vs. pla-
cebo A + active B) for trials involving comparisons be-
tween two or more experimental treatments with differing
routes of administration [9].
Such matching procedures are often challenging to
design, may be time-consuming and increase the cost of
trials. The scientific ideal of developing fully matched
interventions will often have to be weighed against the
concrete increase in cost and logistic challenges when
planning and running a trial. It is therefore not surpris-
ing that matching procedures in drug trials are not
always successful. For example, in a randomised trial of
oral typhoid vaccine vs. placebo investigators discovered
that taste and aroma was distinct for the experimental
vaccine [11]. In another trial of oral zinc vs. calcium
lactate placebo for common cold, Eby and colleagues
reported that about half of the patients randomized
to the experimental zinc treatment noted the telltale
metallic aftertaste of zinc [12].
However, we do not know how often inadequate
matching occurs in drug trials. A reliable assessment of
the proportion of drug trials with inadequate matching
would be of interest to readers of trial publications, to
funders, to investigators running a trial and to researchers
conducting systematic reviews and formally assessing the
risk of bias due to inadequate blinding.
Thus, we decided to systematically review matching
quality studies. Our primary objective was to assess the
proportion of studies that concluded inadequate matching;
our secondary objective was to describe mechanisms for
inadequate matching.
Methods
Search strategy
We searched PubMed and Google Scholar from inception
onwards. Our core search string was “clinical trial” AND
“(blind* OR mask* OR match*) AND (drug OR placebo)
AND (taste OR smell OR appearance) (Additional file 1).
We searched references of eligible studies obtained and
used Web of Science Citation Index to access publications
that referenced the initial “seed articles” (Fig. 1). Our last
formal search was conducted on 14 April, 2014.
Eligibility criteria
We included studies of matching quality, i.e. studies that
assessed whether supposedly indistinguishable experi-
mental and control drug interventions from randomized
clinical trials could be distinguished due to physical
properties (e.g. colour and appearance, smell, taste, or
texture). We included studies where a group of assessors
was asked to identify differences in one or more inter-
ventions pairs (for example experimental and control
tablets) from one or more trials, and asked to categorize
the interventions (either into two different interventions
or into experimental and control). We also included
pilot trials of treated patients or volunteers, but only if it
was very unlikely that patients or volunteers could iden-
tify intervention type through their pharmacological ef-
fect. For example, in a study of zinc for common cold,
healthy participants took interventions in a pilot study
of only 14 h [13].
We excluded studies of device interventions (for ex-
ample acupuncture) or psychological interventions, studies
involving assessments of the properties of a single trial
intervention (e.g. control only) and experimental studies
where the compared interventions were intentionally pre-
pared with differences (and not intended for use in a real
clinical trial) (Fig. 1).
Data extraction
One author (SB) scanned titles and abstracts from PubMed
and text fragments from Google Scholar, retrieved and
assessed full texts of potentially eligible studies.
Based on a pre-tested form, two authors (SB, AH or
MW) independently extracted data on the experimental
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and control interventions, the clinical conditions con-
cerned, the formulation types, physical properties com-
pared, the description of comparison methods, information
on who developed or provided the compared interven-
tions, descriptions of persons involved in the assessments,
main outcomes assessed, any statistical analysis, and the
authors’ conclusion.
Analysis
We anticipated substantial methodological differences be-
tween the matching quality studies; for example the criteria
for deciding inadequate matching, statistical approach, the
number and types of sensory qualities which were assessed,
number of assessors, the information given to assessors,
and the pharmaceutical preparation formats. We therefore
planned to summarize the data qualitatively without a
formal meta-analysis.
We based our primary analysis on the conclusions of
each study report.
As a basis for supportive analyses we defined both a low
and a high threshold for inadequate matching. We defined
“low threshold” for inadequate matching to mean that the
interventions were considered inadequately matched if at
least one assessor (of a group of assessors) had found obvi-
ous differences between the interventions, or if a sensory
quality had been left unexamined in a matching study be-
cause a good match was regarded unfeasible (for example
if taste was excluded from a study where the experimental
intervention had a distinctly bitter taste). In case this in-
formation was not available in a study, we defined “low
threshold” pragmatically on a case-to-case basis. A high
threshold meant that the interventions were considered
inadequately matched only if more than 75 % of assessors
had found obvious differences between the interventions.
Fig. 1 PRISMA Flow of database search for identifying eligible studies
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In case this information was not available in a study,
we defined “high threshold” pragmatically on a case-
to-case basis.
Results
We read 170 full articles based on 5368 PubMed abstracts,
8284 hits from Google Scholar, and 52 citations in Web of
Science Citation Index (Fig. 1). We excluded 163 full text
articles (Fig. 1). Thus, we identified seven articles [13–19],
published from 1974 to 2011, describing a total of 36
eligible matching quality studies.
General characteristics
The 36 trials involved were mainly conducted in psych-
iatry, cardiology, pulmonology and infectious diseases
(Table 1). The most frequently compared formulation type
was tablet. The majority of the compared interventions
were provided by pharmaceutical companies (Table 1). In
most cases the assessment of the matching quality was
conducted by a small group of persons recruited from the
investigation team or volunteers (e.g. students and admin-
istrative staff members) (Tables 2). Twenty-eight trials
(78 %) were conducted before 1977.
Twenty-two matching quality studies were based on a
defined cohort of randomized clinical trials. The cohort
consisted of all “double-blind” trials conducted in the
UK within one year (August 1973 to August 1974), and
published in The Lancet, BMJ, Clinical Allergy or Current
Medical Research and Opinion (the “UK trial cohort”) [16].
Fourteen other matching quality studies were not based
on a defined trial cohort.
Primary analysis
Inadequate matching was concluded for 16 of the 36
(44 %) trials (Table 3). The mechanisms involved were
typically differences in taste (17/36; 47 %), colour (15/36;
42 %), and appearance (e.g. texture, shape, consistency)
(13/36; 36 %).
Secondary analyses
Based on a high threshold for inadequate matching, 12 of
the 36 trials (33 %) were inadequately matched (Table 3).
Based on a low threshold for inadequate matching, 26
trials (72 %) were inadequately matched (Table 3).
Inadequate matching was concluded for 7 of 22 trials
based on the UK trial cohort (32 %). In contrast, inad-
equate matching was concluded for 9 out of 14 trials
(64 %) not based on a trial cohort.
The proportion of inadequate matching did not seem
to depend on publication year. Trials published before
1977 had inadequate matching in 4 of 10 trials (12/
28;43 %). This was also the case for trials published be-
tween 1977 and 2000 (2/5;40 %), and for trials published
after 2000 (2/3;67 %).
Results of the individual publications
Hill and colleagues [16] studied supposedly matching
interventions from a defined cohort of 22 trials (i.e. the
UK trial cohort, see above). Samples of intervention
pairs included different formats, for example tablets and
capsules. A group of four assessors independently com-
pared matched interventions (i.e. experimental-control)
(Table 2). In addition, randomly mixed into the sequence
of such intervention pairs, the same assessors compared
a number of identical interventions (e.g. control-control).
The assessors were “without knowledge of the experimen-
tal design”. For each trial, the proportion of assessments
reported as different for the truly identical intervention
Table 1 Characteristics of included matching quality studies
Characteristics n = 36 (%)
Specialty
Psychiatry 6 (17)
Cardiology 5 (14)
Respiratory medicine 5 (14)
Infectious diseases 5 (14)
Neurology 2 (6)
Rheumatology 2 (6)
Dermatology 2 (6)
Complementary-alternative medicine 2 (6)
Gastroenterology 1 (3)
Medicala 3 (8)
No information 3 (8)
Formulation types
Tablet 17 (47)
Capsule 12 (33)
Liquid (injection and oral medicament) 2 (6)
Ointment 2 (6)
Aerosol 2 (6)
Nasal spray 1 (3)
Type of control intervention
Placebo 33 (92)
Active 3 (8)
Producer of the interventions
Pharmaceutical company 25 (69)
Investigators 1 (3)
Not reported 9 (25)
Pharmacy 1 (3)
Method of comparison
Group of assessors
Assessors n = 4 26 (72)
Assessors n = 32-52 8 (22)
Pilot trial 2 (6)
aSpecific medical sub-specialties unclear
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Table 2 Characteristics of included publications
Paper General information Assessment methods Drug format (Number trials),
sensory quality
Analysis Basis for deciding inadequate
matching
Hill and colleagues, 1976 22 trials (11 parallel group trial
and 10 cross-over trial), de
scribed as “double-blind”,
conducted in the UK over
12 months in 1973–74 and
published in four journals
(e.g. BMJ and Lancet).
Out of 32 eligible trials 13 did
not participate. Of the 19
remaining trials 3 were
multi-armed, providing a
total of 22 trial comparisons.
In 19 trials the control
was placebo.
Drug companies produced
the trial interventions
Four assessors (medical and
administrative staff) were twice
provided with 4 interventions
from each trial. The assessors
were “without knowledge of
the experimental design”
The 4 interventions consisted
of 2 experimental and 2
controls), and assessors
conducted 6 comparisons
independently: (2 × the same
interventions [e.g. control vs.
control] and 4 × matched
interventions [intervention vs.
control]). In total, each assessor
did 4 comparisons per trial of
identical interventions and 8
comparisons of matched
interventions.
The number of sensory
qualities involved differed
depending on drug format,
providing a potential number
of assessments per trial with
tablets or capsules of 64
(identical interventions) and
128 (matched interventions)
Tablet (11), colour, shape
and appearance, smell, taste
For each trial, the proportion
of assessments reported as
different for identical
interventions (control vs.
control) (false positive rate)
was subtracted from the
proportion of assessments
reported as different for the
matched interventions:
35 %, 16 %, 41 %, 34 %, 6 %,
42 %, 43 %, 49 %, 15 %, 43 %,
60 %, 60 %, 42 %, 69 %, 27 %,
0 %, 0 %, 0 %, −2 %, 1 %,
20 %, 59 %
Based on a qualitative
assessment the investigators
decided which trials were
inadequately matched
(“obvious differences” were
detected by all 4 assessors)
Capsule (5), colour, shape
and appearance, smell, taste
Aerosol and nasal spray (3),
the container, smell and
taste of aerosol
Ointment (2), colour, appearance
and consistency, smell
Liquid (1), the ampoule, colour
and liquid consistency
Blumen-thal and
colleagues, 1974
6 trials (type not reported),
described as “double blind”.
Trials were selected from those
the investigators had been
involved in because research
assistants had noted differences
between experimental
and controls
In all six trials the control
was placebo.
It was not reported who
produced the trial interventions
Fifty-two assessors (Students,
spouses, lab scientists,
secretaries) served as assessors.
In one part of the study
(“patient-simulated”) 32 assessors
examined a container with 6 trial
interventions from each trial
independently (from 5 trials: 3
experimental and 3 controls,
and in one trial: 2 experimental
of one type, 2 experimental of
another type and 2 controls).
Assessors were instructed to
decide whether interventions were
all one type or not, and to
categorize them accordingly.
The second part of the study
(“experimenter-simulated”) involving
20 assessors was identical to the first
part, but they were told specifically that
the 6 interventions definitely consisted
of both experimental and controls.
Tablet (4), Sensory qualities not
specified.
For each trial, the proportion of
assessments for which assessors
correctly separated all
experimental intervention
from placebo intervention
was calculated.
For the “patient-simulated
study” the proportions were:
19 %, 36 %, 82 %, 19 %,
0 %, 100 %
For the “experimenter-stimulated
study” the proportions were:
90 %, 85 %, 85 %, 90 %, 0 %, 100 %
Based on a Chi2 test the
authors decided for each trial
whether assessors were able
to differentiate better than
chance between
experimental and control
interventions.
Capsule (1), Sensory qualities
not specified.
Liquid (1), Sensory qualities
not specified.
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Table 2 Characteristics of included publications (Continued)
Walter and colleagues,
2005
1 trial (parallel group),
described as “double-blind”.
The study was a pre-trial
assessment of blinding
integrity.
The control was placebo.
Drug company produced
trial interventions
Four assessors (“study investigators”)
were asked to examine
independently a package of 10
tablets. The assessors were informed
that it contained an equal number
of experimental and control
interventions.
Tablet (4), Taste and appearance The number of correctly
assigned tablets were recorded
for each assessor
Based on a Chi2 test the
authors decided whether
assessors were able to
differentiate better than
chance between
experimental and control
interventions.
Fai and colleagues, 2011 1 trial (parallel group), described
as “double-blind”. The study was
a pre-trial assessment of
blinding integrity.
The control was placebo.
The trial investigators produced
the trial interventions.
49 “adults” served as assessors.
It was not reported how many
interventions each assessors
examined or what information
was provided to assessors.
In one part of the study 15
assessors examined the
packaging (box and bottle).
In a second part of the study 11
assessors examined the capsules.
In a third part of the study 23
assessors tested “the overall
result” by guessing whether
an intervention was control
or experimental.
Capsule (1), The appearance and
texture of package and capsule,
and smell of capsule content.
Taste was excluded from the
assessment because “the taste
was not adjusted with bitter agent”
Each assessor of packaging and
capsules scored each property
(exactly identical = 3 very close
to unanimous = 2; significant
difference = 1; inconsistent 0).
The “overall result” was based
on a comparison between
actual intervention status and
guessed status.
Based on Fischer’s exact test
the authors decided whether
assessors were able to
differentiate better than
chance between
experimental and control
interventions.
Dupin-Spriet and
colleagues, 1993
3 trials (type not reported)
The control was placebo
Not reported who provided
the trial interventions
Four assessors (type not reported)
were provided with 8 pairs of
tablets from each trial. The
information, if any, provided to
the assessors on the distribution
of experimental and control
interventions was not reported.
The 8 intervention pairs consisted
of 4 matching pairs (experimental
vs. controls), and 4 identical pairs
(e.g. control vs. control)
Tablet (3), appearance (shape,
colour, surface)
For each trial, the proportion of
assessments reported as different
for the identical interventions
(false positive rate) was
subtracted from the proportion
of assessments reported as
different for the matched
interventions:
Based on Fischer’s exact test
the authors decided for each
trial whether assessors were
able to differentiate better
than chance between
experimental and control
interventions.
Wen and colleagues,
2004
1 trial (parallel group)
Pharmacy provided trial
intervention
32 assessors (e.g. doctors, nurses,
graduate students) were provided
with two bottles of experimental
and control interventions that they
examined independently.
One group of 10 assessors
performed “placebo test”.
One group of 22 assessors
performed a “simulative test”.
It was not reported whether the
experimental and control
interventions were paired during
the assessments
Capsule (1), bottle and capsule
appearance, bottle label and
notes, size, shape, quality,
colour, smell, taste, and
capsule content
Proportion of assessments
found “not uniform” on specific
qualities and overall was
calculated.
Based on Fisher’s exact test
the authors decided whether
assessors were able to
differentiate better than
chance between
experimental and control
interventions.
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Table 2 Characteristics of included publications (Continued)
Farr and colleagues,
1987
2 pilot-trials (parallel group)
Drug company provided
intervention
The control was placebo
Two pilot-trials (low and high dose
zinc) randomizing assessors (students
and university employees) to
experimental or control. Assessors
were informed that one of the
compared substances had shown
possible effect, and that they would
be asked to decide whether they
were receiving an “active” or an
“inactive” compound.
In the first pilot-trial 224 assessors
were allocated to 30 mg zinc or
placebo (0.0004 mg denatonium
benzoate)
In the second pilot-trial, 300 assessors
were allocated to 23 mg zinc or
placebo A (denatonium benzoate
0.00125 mg) or placebo B
(denatonium benzoate 0.0025 mg)
Assessors ingested tablets 8 times
over one day (14 h). After the
fifth tablet assessors filled out a
structured questionnaire.
Tablet (2), bitter taste, aftertaste,
palatability and guesses as to
whether they believed they were
receiving active or placebo.
Proportions of each assessment
(e.g. bitter taste) was compared
between trial groups (i.e.
experimental and control
groups)
Based on a Chi2 test the
authors decided whether
proportions of each
assessments (experimental
and control) differed more
between trial groups than
expected by than chance.
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pairs (e.g. control–control) was a measure of observer
error (i.e. false positive fraction), and was subtracted from
the proportion of assessments reported as different for the
matched interventions. No formal statistical analysis
was conducted, and the decision of inadequate match-
ing was based on a qualitative assessment. The inves-
tigators’conclusion was inadequate matching in seven
of 22 (32 %) trials.
Blumenthal and colleagues [17] studied supposedly
matching interventions from six trials the investigators
had been involved in. The trials compared antidepres-
sants or anxiolytics to placebos (content not reported).
The drug formats were tablet (four trials), capsule (one
trial), and oral liquid (one trial). There were two groups
of assessors. One group of 32 assessors was asked to de-
cide whether six interventions (e.g. tablets) from each
trial differed, and if so, to categorize interventions into
the two groups (Table 2). A second group of 20 assessors
were specifically told that the six interventions consisted
of different types. Both groups of assessors were able to
differentiate between experimental and placebo interven-
tions significantly better than chance in five trial interven-
tions, the exception being an antidepressant capsule used
in one trial. A few assessors (number not specified) also
tasted the interventions and reported that “the active
medications” numbed the tongue. The investigators’
conclusion was inadequate matching in five out of
the six trials.
Walter and colleagues [15] studied supposedly matching
oral antibiotic (amoxicillin) and placebo (type not re-
ported) tablets for childhood pneumonia from one ran-
domized trial [20]. Four assessors were asked to examine
a package containing ten tablets and to divide them into
two groups of five each thought to contain the same drug
type (Table 2). The primary concern was whether the
interventions tasted differently. The investigators con-
cluded adequate matching based on taste. However,
two of the four assessors were unexpectedly able to
distinguish between the antibiotic and placebo based
on the appearance. Thus, the investigators’ conclusion
was inadequate matching.
Fai and colleagues [14] studied supposedly matching
herbal preparations (Danshen and Gegeng) and placebo
(starch with caramel) for the prevention of cardiovascu-
lar disease from one randomized trial [21]. Three groups
of assessors conducted the study; a group of 15 assessors
examined the appearance and texture of box and bottle,
a second group of 11 assessors examined the appearance
and texture of capsule and a third group of 23 assessors
tested “the overall result” by guessing whether an inter-
vention was experimental or placebo. Taste was excluded
from the assessment because “the taste was not adjusted
with bitter agent”. The herbal and placebo interventions
were reported as “close to uniformity” in package and la-
beling; capsules were “very identical” and the overall
comparison indicated that there were no detectable dif-
ferences between herbal and placebo preparations in the
properties assessed. The investigators’ conclusion was
adequate matching based on properties tested.
Dupin-Spriet and colleagues [18] studied supposedly
matching tablets (content not reported) and placebo
(type not reported) for clinical conditions (not reported)
from three randomized trial. There was no information
on instructions given to assessors. A group of four
assessors were asked to examine eight pairs of tablets
consisting of four matching pairs and four identical
pairs, and to note possible differences in appearance
(Table 2). The assessors were able to differentiate between
Table 3 Main and supplementary results
Paper Main results:proportion of trials with inadequate matching
based on the conclusion of the publications
Supplementary results: Proportion of trials with
inadequate matchingbased on high/low thresholdsa
High threshold Low threshold
Hill and collegues, 1976 7 of 22 trials 6/22 trials 14/22 trials
Blumenthal and colleagues, 1974 5 of 6 trials 5/6 trialsb 5/6 trials
Walter and colleagues, 2005 1 of 1 trial 0/1 trial 1/1 trial
Fai and colleagues, 2011 0 of 1 trial 0/1 trial 1/1 trialc
Dupin-Spriet and colleagues, 1993 1 of 3 trials 0/3 trials 3/3 trials
Wen and colleagues, 2004 1 of 1 trial 1/1 trials 1/1 trials
Farr and colleagues, 1987 1 of 2 trials 0/2 trialsd 1/2 trialse
aThe high thresholds are in most cases based on at least 75 % of assessors finding clear differences. The low thresholds are in most cases based on 25 % of assessors
finding clear differences
bTwo groups of assessors were involved. In one group (patient-simulated), only in one trial did 75 % or more of assessors find clear difference between experimental
and control intervention. In the second group of assessors (experimenter-simulated), over 80 % of assessors found clear differences in five out of six experimental and
control drugs
cTaste was excluded from the study because “taste was not adjusted with bitter agent” though the experimental intervention most likely had a more bitter taste
dBased on chance alone, 50 % of assessors would be expected to correctly guess intervention types. We defined high threshold to imply that at least 75 % of
assessors randomized to the experimental intervention perceived being on the experimental intervention
eSignificantly more than 50 % of assessors randomized to experimental group perceived to have received the experimental intervention
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the experimental and placebo tablets in one of the three
pairs. The investigators ‘conclusion was inadequate
matching in one out of three trials.
Wen and colleagues [19] studied a supposedly match-
ing herbal preparation (Shengmai capsule) and a placebo
(type not reported) for chronic heart failure in one ran-
domized trial. One groups of ten assessors performed a
“placebo test” involving examination of the appearance,
bottle label, odour, taste, capsule content. Another group
of 22 assessors performed a “simulative test” involving
examination of overall uniformity of experimental and
placebo interventions. Each assessor examined “two bot-
tles” of experimental and placebo capsules (Table 2).
The experimental intervention was found to be identical
to placebo in bottle appearance, label and capsule but to
differ in odour, taste and texture of capsule contents.
The investigators’ conclusion was inadequate matching.
Farr and colleagues [13] conducted two pilot-trials of
zinc gluconate tablets (30 mg tablet for high-dose test I;
23 mg for low-dose test II) and supposedly matching
placebos (dermatonium benzoate) for common cold.
These two-pilot trials preceded the subsequent two full
trials [22]. In the first pilot-trial 224 assessors were allo-
cated to 30 mg zinc or placebo (0.0004 mg denatonium
benzoate). In the second pilot-trial, 300 assessors were
allocated to 23 mg zinc or placebo A (denatonium
benzoate 0.00125 mg) or placebo B (denatonium benzo-
ate 0.0025 mg). Assessors ingested tablets 8 times over
one day (14 h), and filled out a structured questionnaire
(Table 2). They were informed that one of the tablets
(but not which one) had shown possible efficacy in the
treatment of common cold and that they would be asked
to decide whether they were receiving an active or
inactive tablets based on the taste, aftertaste and palat-
ability. For the high-dose test, assessors randomised to
30 mg zinc were more likely to report intervention as
bitter and unpleasant and thus concluded they were on
experimental intervention. For the low-dose taste test,
assessors randomised to 23 mg zinc were less likely to
report the intervention as bitter with no significant
difference in proportion of zinc and placebo recipi-
ents believing they were on experimental intervention.
The investigators’ conclusion was inadequate matching in
one out of two pilot-trials.
Discussion
We identified 36 studies of the matching quality of ex-
perimental and control interventions in blinded rando-
mised drug trials. Sixteen of the 36 studies (44 %)
concluded inadequate matching. The proportion of in-
adequate matching seemed to vary according to study
design, especially variations in thresholds for inadequate
matching and whether a study was based on a defined co-
hort of trials or not. Typical mechanisms of inadequate
matching were differences in taste or colour. Studies of
matching quality in contemporary trials were rarely pub-
lished but showed similar results as for older trials.
Strengths and weaknesses of the study
To our knowledge, this is the first systematic review of
studies that investigated the quality of matching of drug
interventions in blinded randomised clinical trials. We
identified a fairly large number of studies, which involved
a broad range of pharmacological formulations and
methodological approaches.
Studies of matching quality in randomized trials are
rarely published, and are not routinely reported in a way
that makes them easily accessible through standard litera-
ture searches. We developed a detailed search strategy
involving both a full-text database and Web of Science
Citation Index. However, we cannot exclude that some
studies have not been identified, especially unpublished
comparisons [23].
Twenty-eight of the 36 studies we did identify were
based on trials conducted before 1977. The blinding pro-
cedures in these early trials are not necessarily represen-
tative for blinding procedures in more contemporary
ones. However, blinding was considered one of the most
important methodological aspects of a randomized trial
during the 1970′s, so it is likely that the matching proce-
dures were well prepared in many cases. Also, we found
no clear tendency for contemporary trials to more often
have adequate matching, though this was based on a
modest number of studies.
The methods of the included matching studies varied
considerably. The proportion of inadequate matching in
studies based on a defined trial cohort (i.e. the UK trial
cohort) was lower (32 %) than the proportion of inad-
equate matching in studies not based on a trial cohort
(64 %). Possible explanations for this variation are ana-
lysis methods and publication bias. In the UK trial co-
hort calculation of inadequate matching involved a
correction for false positive assessments (see Results),
implying a more conservative assessment compared to
most of the other studies. Furthermore, the risk of publi-
cation bias may be substantially higher in trials that are
not part of a cohort as they may tend to conduct and
report comparisons more frequently when differences
between the physical properties of treatments were sus-
pected and/or observed. For example, Blumenthal and
colleagues initiated their study of six trials after “re-
search assistants noticed that the active drugs could be
distinguished from the placebos by small differences in
physical properties” [17].
The thresholds for inadequate matching differed from
study to study. For example, the threshold for inadequate
matching implemented by Blumenthal and colleagues [17]
involved the correct separation of all experimental from
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control interventions by each assessor. Other studies
implemented less strict criteria. For example Walter and
colleagues, considered statistically significant assignment
of experimental and placebo tablets into respective groups
by assessors and not necessarily correct assignment of all
the tablets [15]. In a supportive analysis, we applied a high
threshold for defining inadequate matching, and still
found that about 1 out of 3 trials had not adequately
matched interventions. Thus, the exact proportions will
differ depending on which criteria for inadequate matching
is adopted, but our overall qualitative conclusion is
robust to threshold variations.
All the studies except the UK cohort employed signifi-
cance tests to decide whether there was sufficient evi-
dence of poor matching (Table 2). While laudable in
principle, it means that the individual experimental setup
(number of observations and other design details) affects
conclusions, making generalizations challenging. In par-
ticular, studies with few assessors and assessments have a
high risk of overlooking an existing mismatch (i.e. type 2
error). Nonetheless, many of our trials do reach a conclu-
sion of inadequate matching despite being fairly small.
The authors of the UK cohort, on the other hand, try to
judge by the presumed medical importance of the detec-
tion rates, but their subtraction of a false positive fraction
(Table 2) may lead to underestimation (Additional file 1).
More methodological work is needed to establish the
best approach.
Other studies
The problem of inadequate matching has primarily been
discussed in the context of non-pharmacological trials.
Studies of matching in that class of trials have reported
findings comparable to ours [24–27]. For example, in
some studies comparing the perceptible physical proper-
ties of real vs. sham acupuncture (e.g. perception of
needle skin penetration) have reported that participants
were able to differentiate between experimental and con-
trol treatments [24, 25], while other studies have found
that participants could not differentiate between the two
types of interventions [26, 27].
In a previous study we analyzed 300 randomised clinical
trial publications and found none that reported a pre-trial
matching quality study [28]. In our present study we also
find that few matching quality studies are published com-
pared to the number of randomized clinical trials adopting
matching. We suspect, however, that matching studies are
carried out much more often as a quality assurance
exercise before starting a randomized trial, but that
the vast majority of these studies remain unpublished.
Mechanism
Good manufacturing practice guidelines recommend strat-
egies aimed at reducing the risk of mix-ups between
experimental and control interventions [29]. This suggests
that drug companies (and other producers of drug trial
interventions, such as pharmacies) sometimes fail to
standardize their manufacturing process. Experimental
and control interventions may be produced at different
sites, or not in sequence. For example, placebo production
may be postponed until trial contracts are signed or is rel-
egated to a different plant or to subcontractors. Subtle but
noticeable differences between the experimental and the
control interventions could easily be the result.
It is striking that trial investigators are sometimes un-
aware of the physical aspects of trial intervention prop-
erties that may be inadequately matched. For example,
Walter and colleagues were mainly concerned about the
possibility of patients identifying the experimental inter-
vention through taste [15]. However, unexpectedly, two
of four assessors were able to correctly differentiate be-
tween trial interventions based on appearance. In real
clinical trial settings, other potential sources of unblind-
ing may derive from side effects of treatments and suspi-
cion arising from awareness of laboratory results.
It is important to point out that inadequate matching
does not automatically mean loss of blinding. Loss of
blinding, i.e. unblinding, involves the correct identifica-
tion of which type of trial intervention is the experimen-
tal and which is the control, and not only the ability to
identify a difference between two types of interventions.
Only two of the 36 studies involved the identification of
which intervention was experimental and which was
control [13, 14], though some assessors in a third study
did so without being asked to do it [17].
Pre-trial assessments provide an opportunity for cor-
recting inadequate matching [13–15]. We included three
pre-trial assessment studies. One of the three studies
produced evidence of inadequate matching [15], but the
members of the data monitoring committee and the
principal investigator decided to proceed with the trial
without correcting the flaw. The trial was published in
the BMJ in 2004 [20], but the trial publication did not
report assessment of matching quality, nor was inad-
equate matching mentioned by the authors when they
summarized strengths and weaknesses of the trial [20].
In another study, taste was excluded from the assess-
ment though there was a substantial risk that the experi-
mental intervention had a distinctly bitter taste. This
was not reported in the publication describing the trial
[21]. The last pre-trial assessment study found inad-
equate matching in one out of two pilot trials. In the
subsequent full trials [22], the authors therefore used the
adequately matched formulations.
An unanswered question is which degree of bias is
induced by inadequate matching. Clearly, the degree of
bias in trials with partially unsuccessful matching is
expected to be lower than in trials with no blinding at
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all. Still, it is unclear how much lower. For a significant
bias to occur due to unblinded patients, a substantial
proportion of patients have to note that interventions
are inadequately matched and correctly deduce which is
the experimental intervention. This probably does occur
regularly, especially in trials with clearly inadequate
matching and where both types of interventions are pre-
sented to patients, for example cross-over trials and
split-body designed trials. Parallel group trials with run-in
periods (placebo or experimental) or with double-dummy
procedures may also be at risk. However, without a direct
comparison inadequate matching is more difficult to
note for a patient. A standard parallel group trial with-
out run-in periods or double-dummy procedures may
therefore be fairly robust to patient unblinding due to
imperfect matching.
In contrast, the risk of bias caused by unblinding of
health care personnel and outcome assessors due to in-
adequate matching may be substantial also in standard
parallel group trials. Investigators normally have easy
and repeated access to both types of interventions, so
minor imperfections in matching will more readily be
noted, and the unblinding of just one or a few persons
may easily affect a large number of patient assessments.
It is noteworthy that Bluhmenthal and colleagues found
a more pronounced degree of inadequate matching in
their “experimenter-simulated” substudy where assessors
were specifically told that the interventions they were
assessing consisted of both experimental and control in-
terventions than in their “patient-simulated” substudy
where assessors did not know whether the interventions
were all of the same type [17].
The apparently first two published studies of the
matching quality of pharmacological experimental and
control interventions were prominently published in the
1970s [16, 17]. Surprisingly, their disturbing early results
were never followed up comprehensively by subsequent
studies of contemporary trial cohorts. We have only
identified three studies published since 2000 (with find-
ings consistent with that of the earlier studies). This lack
of interest is surprising when considering the traditional
important role of blinding in trial methodology. Nor is it
in accordance with Guidelines on Good Manufacturing
Practice of Investigational New Drugs for Clinical Trials,
which emphasize verification of the effectiveness of
blinding by a check on the physical similarity of experi-
mental and control preparations [30–32]. Regardless, it
appears that since the late 1970′ies the subject of match-
ing in drug trials has largely been withdrawn from the
scientific literature and the accompanying academic
scrutiny. Today the responsibility for designing and
manufacturing matched pharmacological preparations
for clinical trials is dominated by the pharmaceutical in-
dustry. Furthermore, interpretations of any assessments
of the adequacy of matching in clinical drug trials will
often be an internal trial procedure. The results of such
assessments, and any action resulting from the assess-
ment, are rarely communicated to others.
Implications
Our study provides an empirically based framework for
the interpretation of results from blinded randomized
clinical trials of drug interventions.
We interpret the exact proportions of inadequate
matching with reservation. The studies based on a defined
trial cohort were not contemporary, and the newer studies
may involve a considerable risk of publication bias. Still,
the findings are clearly disconcerting. If our result can be
reproduced in a study of contemporary and representative
trials, an important methodological limitation in current
trial methods needs to be corrected.
We furthermore suggest that trial investigators closely
examine the matching properties of the compared treat-
ments. Such pre-trial comparisons of matched preparations
could reveal correctable flaws in the matching thus redu-
cing the risk of unblinding. We also suggest that when such
examinations are carried out, the methods and results are
published, for example in an Additional file 1 to the trial.
It is not entirely clear how matching studies are best
conducted and analysed. Further methodological research
is therefore warranted to assist researchers conducting
and analyzing results from randomized clinical trials that
compare matching interventions.
Conclusion
In this systematic review we identified studies of the
quality of matching of drug interventions in 36 randomized
clinical trials. Sixteen of the 36 studies (44 %) concluded
inadequate matching. Typical mechanisms of inadequate
matching were differences in taste or colour. Studies
of matching quality in contemporary trials are rarely
published, but show similar results as found for older
trials. Inadequate matching in drug trials may be more
prevalent than commonly believed.
Additional file
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